Bresso (Italy), Villigen (Switzerland) and Nijmegen (the Netherlands) – Axxam, leadXpro and MercachemSyncom today announced a strategic alliance that will allow them to offer world-class integrated structure-guided drug discovery services for membrane protein targets.

Axxam and FUJIFILM Cellular Dynamics announce strategic alliance to deliver integrated hiPSC drug discovery solutions Oct 8, 2020 MILAN (Italy) and MADISON (Wis., USA) - Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences...

Axxam announces the launch of Libra Therapeutics to develop novel therapies targeting neurodegenerative diseases Sept 24, 2020 Milan (Italy) – Axxam is proud to announce that Libra Therapeutics, a privately held US biotech company founded in mid-2019 by Axxam and...

Selonterra and Axxam Enter into Drug Discovery Collaboration June 16, 2020 San Mateo, California (USA) and Milan, Italy - Selonterra, Inc., a biotechnology company developing transformative therapies for neurodegenerative disorders, and Axxam S.p.A., a leading...

Axxam enters into Drug Discovery Collaboration with Vivozon for CNS Indications May 12, 2020 Axxam announces a collaboration with Vivozon Inc. with the aim to support Vivozon in the development of innovative small molecule drugs for the treatment of patients with...

Axxam supports drug discovery efforts to identify novel inhibitors for SARS-CoV-2 Apr 30, 2020 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced its commitment to support the identification of antiviral therapies to...

Axxam and ERS Genomics announce CRISPR-Cas9 license agreement to enhance discovery services Apr 2, 2020 Milan (Italy) and Dublin (Ireland) - 2 April 2020 - ERS Genomics Limited (“ERS Genomics”), which was formed to provide broad access to the foundational CRISPR-Cas9...

Axxam and ZoBio Form a Strategic Alliance Integrating their Drug Discovery Services Platforms Jan 14, 2020 Milan (Italy) and Leiden (Netherlands) - 14 January 2019 - Axxam, the leading drug discovery company with expertise in early phase discovery biology, and ZoBio,...

Dr. Thilo Enderle appointed as new Chief Executive Officer of Hit Discovery Constance GmbH Jan 10, 2019 Milan (Italy)/Constance (Germany) - Axxam announces the appointment of Dr. Thilo Enderle as Chief Executive Officer of Hit Discovery Constance (HDC), a joint...

Axxam SpA expands to Denmark; opens office in Copenhagen Sep 27, 2018 Axxam SpA (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds,...